What drove ABBV's consistent earnings beat in 2024?

AbbVie's consistent earnings beat in 2024 can be attributed to several key factors:

1. **Strong Performance in Neuroscience and Oncology Segments**: AbbVie's neuroscience portfolio, led by Vraylar and Qulipta, saw significant growth, contributing to the overall revenue increase. The oncology portfolio also performed well, with Venclexta experiencing a 9.0% increase in revenues. These segments' strong performances offset some of the challenges faced by the immunology sector due to biosimilar competition.
2. **Strategic Acquisitions**: AbbVie's strategic acquisitions, such as those of Landos Biopharma and Celsius Therapeutics, have enhanced its pipeline in inflammatory diseases and expanded its neuroscience portfolio, positioning the company for sustained growth. These acquisitions have likely contributed to the company's financial performance.
3. **Effective Management of Humira Erosion**: Despite the impact of biosimilar competition on Humira sales, AbbVie has effectively managed the erosion of this key product, with Skyrizi and Rinvoq showing significant revenue growth. The company's diversified portfolio and strategic focus on growing new products have helped mitigate the impact of Humira's decline.
4. **Revenue Growth in Emerging Markets**: AbbVie has seen growth in emerging markets, particularly in regions like China and Europe, which has contributed to its revenue growth. The company's international performance has been a key driver of its financial success.

In summary, AbbVie's consistent earnings beat in 2024 can be attributed to strong performances in its neuroscience and oncology segments, strategic acquisitions, effective management of Humira erosion, and revenue growth in emerging markets. These factors have collectively contributed to the company's robust financial results.